Department of Allergy, St. Luke's-Roosevelt Hospital, New York, New York 10022, USA.
Ann Allergy Asthma Immunol. 2010 Nov;105(5):328-36; quiz 337, 358. doi: 10.1016/j.anai.2010.08.008.
To review major milestones in the development of subcutaneous allergen immunotherapy in 20-year segments.
Review of the literature available in textbooks and journals.
Articles and books addressing major achievements in the development of subcutaneous allergy immunotherapy were selected for inclusion in this review.
Immunotherapy administration has improved the lives of possibly millions of patients with hay fever. Asthmatic symptoms have been relieved if not ablated in millions as well. Insect venom hypersensitivity became treatable and highly effective. In the beginning years of immunotherapy, it was clear that immunotherapy worked; in the later years, the mechanisms for this efficacy were discovered. In this case, the therapy preceded its validation. Methods, materials, and safety have vastly improved. Postulated mechanisms explain much but not everything.
There is still research to be accomplished, improvements to be made, and, of course, patients to be made well.
回顾 20 年来皮下变应原免疫治疗发展的主要里程碑。
教科书和期刊中现有文献的回顾。
选择了探讨皮下过敏免疫治疗发展的主要成就的文章和书籍,纳入本综述。
免疫疗法的应用改善了可能数以百万计的花粉热患者的生活。哮喘症状也得到了缓解,如果没有缓解,也得到了缓解。昆虫毒液过敏也变得可治疗且非常有效。在免疫疗法的早期,很明显免疫疗法是有效的;在后来的几年里,发现了这种疗效的机制。在这种情况下,治疗先于验证。方法、材料和安全性都有了很大的提高。推测的机制解释了很多,但不是全部。
仍有研究要做,需要改进,当然,还有患者需要治愈。